Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model.
Sign Up to like & getrecommendations! Published in 2023 at "Obesity"
DOI: 10.1002/oby.23771
Abstract: OBJECTIVE Sodium-glucose cotransporter 2 inhibitors (SGLT2i) promote urinary glucose excretion, induce weight loss, and reduce fat accumulation. The effects of the SGLT2i dapagliflozin (DAPA) on subcutaneous (SC) and visceral (VIS) adipose tissue function remain unclear.… read more here.
Keywords: insulin resistant; adipose tissue; resistant canine; dapa ... See more keywords